Kodu・Aktsiate loetelu・Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Avatud

SektorTervishoid

3.44 1.18

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.32

Max

3.51

Põhinäitajad
By Trading Economics
Sissetulek	-5.1M -48M
Aktsiakasum	-0.42
Töötajad	202
EBITDA	-8M -45M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+246.04% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-39M 355M
Eelmine avamishind	2.26
Eelmine sulgemishind	3.44

Uudiste sentiment

By Acuity

15%

85%

25 / 340 Pingereas Healthcare

Rocket Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 22:01 UTC

Event

Rocket Pharmaceuticals shares are lower in after-market trading despite a positive clinical safety update on its Phase 2 trial for RP-A501.

31. juuli 2026, 22:01 UTC

Rocket Pharmaceuticals shares declined in after-hours trading, continuing a downward trend since Friday's close. The stock remains below its 20-day moving average.

30. juuli 2026, 21:51 UTC

Rocket Pharmaceuticals is lower in after-market hours, reflecting declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

29. juuli 2026, 20:52 UTC

Rocket Pharmaceuticals shares are lower in after-market hours amid a broader market decline driven by rising crude oil prices and geopolitical tensions.

28. juuli 2026, 19:22 UTC

Rocket Pharmaceuticals Inc is trading lower today, reflecting broader market trends. The stock remains below its 20-day moving average and near its one-month trading range low.

27. juuli 2026, 16:16 UTC

Rocket Pharmaceuticals is trading higher today, recovering from an earlier dip. Broader market volatility follows a notable decline in oil prices amid geopolitical developments.

24. juuli 2026, 19:06 UTC

Rocket Pharmaceuticals is trading lower, extending a five-session decline. Broader market pressures and falling crude oil prices are influencing investor sentiment.

22. juuli 2026, 20:06 UTC

Rocket Pharmaceuticals shares are lower, marking four consecutive sessions of declines. The stock has closed below its 20-day moving average.

20. juuli 2026, 19:46 UTC

News

Rocket Pharmaceuticals shares are higher today amid mixed analyst sentiments, with Wall Street Zen downgrading to "sell" and Chardan Capital maintaining a "buy" rating.

Võrdlus sarnastega

Hinnamuutus

Rocket Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

246.04% tõus

12 kuu keskmine prognoos

Keskmine 11.8 USD 246.04%

Kõrge 16 USD

Madal 10 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Rocket Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Rocket Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

25 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.